Health Journal Online

Tag: variant

  • COVID Nimbus Variant Now Leads the U.S. as Cases Grow in 27 States and Emergency Visits Rise

    COVID Nimbus Variant Now Leads the U.S. as Cases Grow in 27 States and Emergency Visits Rise

    A Summer Wave Is Taking Shape

    COVID-19 has not gone away. A new subvariant has taken over as the dominant circulating strain in the United States, emergency department visits are rising across all age groups, and federal epidemic models now show infections growing or likely growing in at least 27 states as of mid-July 2026.

    The variant, known as NB.1.8.1 and informally called “Nimbus,” accounted for an estimated 43% of sequenced COVID cases in the U.S. during the two-week period ending late June 2026, according to CDC genomic surveillance data, surpassing all other circulating strains to become the dominant U.S. lineage. It is a descendant of the JN.1 Omicron lineage, first detected globally in early 2025 and identified in the United States through airport screening programs in March 2026.

    This variant drove earlier surges in China, Singapore, and parts of Southeast Asia before establishing itself in the U.S. — a pattern that health officials have been watching as a leading indicator of domestic wave dynamics.

    Why This Matters

    For most healthy, vaccinated adults, the Nimbus variant appears to cause illness consistent with other recent Omicron descendants: upper respiratory symptoms, sore throat, fatigue, and fever. WHO and CDC have not found evidence of vaccine escape sufficient to cause widespread serious illness in vaccinated populations. It does not appear to cause a higher rate of severe illness, hospitalization, or death compared to LP.8.1 and other recent Omicron strains.

    But transmissibility — not just severity — drives surge dynamics. In Singapore, NB.1.8.1 spread at approximately 60% weekly growth rates before becoming dominant, and a variant capable of infecting large numbers of people simultaneously always poses an elevated risk to those who are most vulnerable: older adults, immunocompromised people, and those who have not updated their COVID vaccination.

    Rising emergency department visits are now visible across all age groups — a pattern that appeared before national clinical case counts reflected the underlying trend, consistent with how COVID summer waves have developed in prior years.

    What We Know So Far

    CDC forecasting models as of July 15, 2026 estimate that COVID infections are currently growing or likely growing in at least 27 states, based on the most recent epidemiological trend modeling.

    As of July 12, 2026, COVID test positivity nationally stood at 4.8%, up 1.1% from the previous week. Emergency department visits are also rising across all age groups, according to the CDC’s respiratory illness surveillance data.

    Nine states are currently reporting moderate to very high COVID viral levels in wastewater: California, Florida, Hawaii, Idaho, Louisiana, Nevada, Oregon, South Carolina, and Texas. Wastewater surveillance detects COVID viral particles in sewage before those infections show up in clinical test counts or hospital admissions — typically providing one to two weeks of early warning of rising community transmission.

    WastewaterSCAN, which independently monitors diseases through municipal wastewater systems, reported national COVID levels in the “high” category as of its most recent available data — a more aggressive characterization than the CDC’s current “low” national wastewater reading, reflecting different measurement methodologies.

    Where the Risk Is Highest

    The geographic pattern of elevated wastewater activity — concentrated in the South and West — is consistent with the CDC’s 2026 Summer Outlook, which identified these regions as most likely to see early COVID activity this summer, citing lower recent immunity in populations that had limited COVID exposure last winter.

    Among the states with current high or very high wastewater activity, the most populous are California, Florida, and Texas — states whose combined populations exceed 90 million people. Louisiana and South Carolina, also on the elevated list, have historically had higher rates of chronic conditions that increase COVID severity risk.

    Nimbus has been detected in sequences across multiple U.S. states, with a wide geographic spread already established. The CDC has not published a detailed regional breakdown of variant proportions due to current limitations in sequencing coverage, but the 27-state growth model reflects national-level epidemiological trends.

    What Experts Say

    The Nimbus variant first demonstrated its capacity for rapid spread in Asia, where it drove surges in China, Singapore, and parts of Southeast Asia before being identified in the U.S. through airport monitoring. The pattern from those earlier waves — high transmissibility, widespread community spread, manageable severity in vaccinated populations, but significant risk for the immunocompromised and unvaccinated — is what U.S. health officials are using to calibrate their summer expectations.

    The CDC’s 2026 Summer Outlook identified the South and West as the most likely regions for early summer COVID activity. The current wastewater data is confirming that pattern. Health officials are urging high-risk individuals to verify their vaccination status before exposure opportunities increase with summer travel and large indoor gatherings.

    The current 2025–2026 updated COVID vaccines target the LP.8.1 variant. Health authorities are monitoring whether an NB.1.8.1-specific update to the vaccine formulation will be needed for the fall 2026 vaccine cycle, though no announcement on that question has been made as of mid-July 2026.

    What the Evidence Shows and What It Does Not

    MedicalDaily Evidence Check

    • Variant proportion data: 43% of sequenced cases attributed to NB.1.8.1 as of late June 2026. The CDC notes that its precision in variant proportion reporting is currently “low” due to limited sequencing data; the exact proportion may shift as more samples are processed. The dominant status of the variant is well-established.
    • Severity: Available data from WHO, ECDC, and U.S. surveillance do not show increased severe disease, hospitalization rates, or case fatality compared to recent prior variants. This may change as the wave develops and more clinical data accumulates.
    • Vaccine protection: Current vaccines are expected to retain meaningful protection against severe illness and hospitalization, though their effectiveness against infection with NB.1.8.1 specifically is still being assessed.
    • What is not yet known: U.S.-specific clinical severity data for NB.1.8.1 is still accumulating. The peak of the current wave has not yet been reached in most affected states.

    Who Faces the Greatest Risk?

    COVID continues to cause serious illness and death primarily in specific vulnerable populations:

    • Adults 65 and older, who account for a disproportionate share of COVID hospitalizations and deaths in every recent wave
    • People who are immunocompromised — including those receiving cancer chemotherapy, organ transplant recipients, people with HIV, and those on biologics or corticosteroids
    • People who have not received an updated COVID vaccine in the past year
    • Individuals with multiple chronic conditions — particularly heart disease, diabetes, chronic kidney disease, and obesity
    • Pregnant people, who face elevated risk from respiratory infections
    • People in high-density settings — nursing facilities, group homes, correctional facilities — where transmission risk is amplified

    For younger, healthy, vaccinated adults, the current evidence suggests the Nimbus variant causes illness that is unpleasant but rarely severe.

    Symptoms and Warning Signs to Watch For

    Nimbus appears to cause symptoms consistent with other recent Omicron subvariants. Some patients have reported a more pronounced sore throat — described in some accounts as a “razor blade” sensation — as a notable early symptom. Other common presentations include:

    • Sore throat and upper respiratory congestion
    • Fatigue and body aches
    • Fever or chills
    • Headache
    • Runny nose or cough

    Symptoms that warrant prompt medical attention, particularly in high-risk individuals:

    • Shortness of breath or difficulty breathing
    • Persistent chest pain or pressure
    • Confusion or inability to stay awake
    • Bluish lips or face
    • Oxygen saturation below 94% if monitored at home

    What You Can Do Now

    • Check whether you are up to date on your COVID vaccination. The 2025–2026 updated vaccine is available at most pharmacies and health department clinics, many at no cost. Use vaccines.gov to find a location near you.
    • If you are immunocompromised or in a high-risk category, ask your provider whether you qualify for COVID pre-exposure prophylaxis or treatment options like Paxlovid, should you test positive.
    • Use a high-quality mask — N95 or KN95 — in crowded indoor settings if you are at high risk, particularly in airports, public transit, or large indoor gatherings.
    • If you test positive, isolate to protect others and contact your provider immediately if you are in a high-risk category to discuss whether antiviral treatment is appropriate. Paxlovid is most effective when started within five days of symptom onset.
    • Monitor CDC COVID Data Tracker and your state health department for updated local wastewater and clinical trend data.

    Cost and Access: What Patients Should Know

    Updated COVID vaccines are available at no cost at most pharmacy chains — including CVS, Walgreens, Rite Aid, and Walmart pharmacy — for people with Medicare, Medicaid, or private insurance. For uninsured patients, the CDC’s Bridge Access Program and state vaccination programs provide vaccines at no out-of-pocket cost at participating locations.

    Paxlovid, the antiviral treatment for COVID-19, requires a prescription. It is covered under most insurance plans for eligible patients with COVID-19 who are at high risk of severe illness. Patients without insurance can ask their provider or pharmacist about the Pfizer patient assistance program.

    At-home COVID tests remain available at pharmacies and continue to detect the Nimbus variant, though their sensitivity may be lower early in infection than at 48 to 72 hours after symptom onset.

    What Happens Next

    The summer COVID wave is expected to develop through July and into August in the states currently showing elevated wastewater signals. The CDC updates its COVID epidemic trend forecasts weekly; MedicalDaily will report on significant changes in wave dynamics, vaccination guidance, or variant severity data as they emerge.

    The WHO and FDA are monitoring whether the fall 2026 COVID vaccine formulation should target NB.1.8.1 or a newer variant; decisions on the fall vaccine strain typically come in late summer.

    The Bottom Line

    The Nimbus variant has made COVID the dominant public health story of midsummer 2026, with infections growing in 27 states and ER visits rising nationally. For most vaccinated, healthy adults, this wave is likely to produce an uncomfortable but manageable illness. For older adults, immunocompromised people, and those without updated vaccinations, this summer presents a genuine and preventable risk. Get vaccinated, monitor your local wastewater data, and know how to access antiviral treatment quickly if you are in a high-risk group.

    Source link

  • What Is the New COVID BA.3.2 ‘Cicada’ Variant? Symptoms, Spread, and Risks Explained

    What Is the New COVID BA.3.2 ‘Cicada’ Variant? Symptoms, Spread, and Risks Explained

    The BA.3.2 variant, often called the Cicada COVID variant, has drawn attention as a new COVID variant 2026 due to its unusually high number of mutations. Emerging as an Omicron descendant, it carries more than 50 spike protein mutations, raising questions about transmissibility and immune response. Despite this, early observations show it circulating at low to moderate levels without overtaking dominant strains.

    Understanding how this variant behaves is key to informed awareness rather than alarm. Current data suggests that while it may partially evade immunity, it does not significantly increase severity. Monitoring continues as part of global efforts to track SARS-CoV-2 evolution and ensure public health responses remain effective.

    BA.3.2 Variant Origins and Mutations

    The BA.3.2 variant is an Omicron descendant that likely evolved from the BA.3 lineage, which circulated at low levels earlier in the pandemic. Its reappearance in late 2024 caught attention, as genetic analysis suggests it may have developed undetected for months, possibly in a chronically infected individual.

    Based on a study conducted by the World Health Organization, BA.3.2 carries more than 50 spike protein mutations and over 70 total genetic changes compared to the original strain. Many of these mutations are concentrated in the spike protein, which is responsible for how the virus enters human cells.

    This rapid accumulation of mutations, known as a saltation event, may allow partial immune evasion. However, it may also reduce the virus’s efficiency in infecting cells, limiting its spread. The Cicada COVID variant nickname reflects this hidden evolution, though current data shows it does not outperform dominant Omicron subvariants.

    Cicada COVID Variant Spread Patterns

    The Cicada COVID variant has been detected across multiple regions, including South Africa, Europe, the United States, and Australia. Despite its international presence, it remains at low prevalence levels and has not driven major outbreaks or replaced dominant strains like JN.1 descendants.

    According to the Centers for Disease Control and Prevention, surveillance data shows that emerging variants often circulate at low levels without becoming dominant when they lack a growth advantage. In the case of the BA.3.2 variant, detection rates remain low, typically representing only a small fraction of sequenced cases.

    Wastewater monitoring and clinical data confirm its presence, but not at levels suggesting rapid spread. The new COVID variant 2026 is classified as a Variant Under Monitoring, meaning it is tracked for changes while posing no immediate concern due to its limited transmissibility.

    New COVID Variant Symptoms and Risks

    The new COVID variant 2026 shows a symptom pattern similar to recent Omicron descendants, with mostly mild respiratory effects. According to Johns Hopkins Medicine, most Omicron-related variants continue to produce milder symptoms, especially in vaccinated individuals. Current evidence suggests that while mutations exist, overall risk remains stable and manageable.

    • Symptoms remain similar to Omicron variants: The BA.3.2 variant typically presents with fatigue, sore throat, cough, and mild respiratory discomfort rather than severe complications.
    • No increase in severity or hospitalization: There is no evidence linking this new COVID variant 2026 to higher hospitalization rates or increased mortality compared to other circulating strains.
    • Partial immune evasion observed: Laboratory findings show the variant may reduce antibody neutralization from prior infection or vaccination, though this pattern is common among Omicron descendants.
    • Vaccines still protect against severe illness: Despite reduced neutralization, vaccines continue to provide strong protection against serious outcomes, including hospitalization and death.
    • Overall public health risk remains low: The Cicada COVID variant has not demonstrated increased impact in real-world settings, with stable outcomes across monitored regions and continued surveillance in place.

    Tracking BA.3.2 Variant Evolution and COVID Monitoring

    The BA.3.2 variant represents another step in the ongoing evolution of SARS-CoV-2. As an Omicron descendant with a high number of mutations, it highlights how the virus can change under immense pressure while still following broader patterns seen in recent years. Despite its genetic differences, it has not demonstrated the ability to dominate globally.

    Ongoing surveillance remains essential for tracking how variants behave over time. Monitoring systems, including genomic sequencing and wastewater analysis, provide early insights into emerging trends. These tools help health authorities respond quickly while keeping public communication grounded in evidence rather than speculation.

    What BA.3.2 Means for COVID Awareness Today

    The BA.3.2 variant shows how the virus continues to evolve without necessarily increasing risk. While its mutation profile initially raised concern, real-world data points to stable outcomes, with no major changes in severity or spread. This highlights the importance of looking beyond mutation counts and focusing on actual impact.

    Staying informed and maintaining basic health awareness remains the most practical approach. Vaccination, monitoring updates, and understanding how variants behave help individuals navigate changes without unnecessary worry. The Cicada COVID variant serves as a reminder that not every new variant leads to major shifts in the pandemic.

    Frequently Asked Questions

    1. What makes the BA.3.2 variant different from other variants?

    The BA.3.2 variant stands out in its unusually high number of mutations, especially in the spike protein. This makes it more genetically distinct compared to earlier Omicron descendants. However, these mutations do not necessarily make it more dangerous. Current data shows it behaves similarly to other recent variants.

    2. Why is it called the Cicada COVID variant?

    The nickname comes from the idea that the variant evolved undetected for a long period. Like cicadas that stay underground before emerging, BA.3.2 likely circulated quietly before being identified. This delayed detection is not uncommon with viruses. It reflects gaps in surveillance rather than sudden appearance.

    3. Does the BA.3.2 variant cause more severe illness?

    No, there is no evidence that BA.3.2 leads to more severe disease. Symptoms remain similar to other Omicron variants. Hospitalization and death rates have not increased بسبب this variant. It is currently considered low risk in terms of severity.

    4. Are vaccines still effective against the new COVID variant 2026?

    Yes, vaccines are still expected to protect against severe illness. Even though the variant may partially evade antibodies, immune defenses remain strong. Vaccination continues to reduce the risk of hospitalization and complications. This makes it an important tool for ongoing protection.



    Source link

  • New Covid Symptoms and Variant Signs Explained

    New Covid Symptoms and Variant Signs Explained

    COVID-19 in 2026 still looks, for many people, like a bad cold or flu, but new COVID-19 symptoms linked to each emerging new COVID-19 variant can include an unusually sharp sore throat, stubborn congestion, and lingering fatigue. Because COVID-19 overlaps so closely with other respiratory infections, testing remains essential whenever these symptoms appear.​

    COVID-19 in 2026: How Today’s Symptoms Look

    COVID-19 in 2026 is driven by newer Omicron-lineage variants that mostly target the upper airways rather than deep lung tissue seen early in the pandemic. As a result, many infections present as sore throat, congestion, cough, and fatigue instead of the classic high fevers and severe shortness of breath that dominated earlier waves.​

    In everyday life, that means a person with COVID-19 in 2026 may assume they just have a seasonal cold or mild flu because symptoms come on gradually and often feel familiar. This overlap is part of why public health agencies continue to stress testing rather than symptom guessing to know which virus is actually responsible.​

    Most Common Symptoms of COVID-19 in 2026

    Across clinics and surveillance reports, the most frequently reported COVID-19 in 2026 symptoms include sore throat, dry or tickly cough, nasal congestion or runny nose, fatigue, headache, and mild fever or chills. Muscle aches, sneezing, and a general “worn down” feeling are also common, especially in the first few days of illness.​

    Loss of taste or smell still occurs, but it is less frequent than in early pandemic waves dominated by the original strain and Delta. Some people also report gastrointestinal symptoms, nausea, vomiting, or diarrhea, though these are less common and often appear alongside the core respiratory features.​

    New COVID-19 Symptoms and Standout Variant Features

    Each new COVID-19 variant that circulates in 2026 broadly shares this respiratory profile but can have recognisable touches. The NB.1.8.1 “Nimbus” variant, for example, has been associated with a notably severe, sometimes “stabbing” sore throat early in infection, along with fatigue, congestion, and mild cough.

    Other recent variants like XFG “Stratus” show a strongly cold-like pattern dominated by nasal congestion, cough, and prolonged tiredness.​

    These new COVID-19 symptoms still fit within the broader CDC and WHO lists: fever or chills, cough, shortness of breath, sore throat, congestion, loss of taste or smell, headache, muscle aches, and digestive issues.

    What feels “new” in COVID-19 in 2026 is less about brand‑new symptoms and more about how often they appear, how intense they are (especially the throat pain), and how they cluster with one another.​

    Is COVID-19 in 2026 Just Like a Cold or Flu?

    The symptom overlap with colds and flu is now substantial. Sore throat, congestion, cough, sneezing, low‑grade fever, and fatigue are common to all three, and many people start illness without any sign that one virus, rather than another, is responsible.

    In fact, clinicians emphasise that even experienced doctors often cannot distinguish among COVID-19, influenza, and other respiratory viruses by symptoms alone, according to the World Health Organization.​

    There are still patterns that can offer hints. Influenza tends to strike suddenly with higher fevers, intense body aches, and abrupt exhaustion, while new COVID-19 variant infections often build more gradually with pronounced sore throat, congestion, and longer‑lasting tiredness.

    Allergies, meanwhile, usually bring itchy eyes and sneezing without fever or muscle pain, so the presence of fever, distinct body aches, or gut symptoms should raise suspicion for COVID-19 in 2026 or flu rather than simple hay fever.​

    When to Test and Seek Medical Care

    Because new COVID-19 symptoms are so similar to other infections, health agencies recommend testing whenever someone develops a combination of sore throat, cough, congestion, fever, or unexplained fatigue, especially if there has been recent exposure or a local rise in cases.

    Typical symptoms can appear anywhere from 2 to 14 days after exposure, with many people improving within about a week to 10 days, though cough and tiredness can linger longer.​

    Urgent medical attention is warranted if a person develops trouble breathing, persistent chest pain or pressure, new confusion, difficulty staying awake, or bluish lips or face, as these can signal severe COVID-19 or another serious condition.

    People in high‑risk groups, older adults, those with chronic illnesses, or individuals with weakened immune systems, are advised to contact a clinician early, because they may qualify for antiviral treatment that reduces the chance of hospitalisation.​

    Long COVID and Lingering Symptoms

    Even in the era of new variants, long COVID remains a concern. Some people experience fatigue, shortness of breath, brain fog, sleep issues, or mood changes for weeks or months after the initial infection has resolved, regardless of how mild the first illness appeared, as per the Centers for Disease Control and Prevention.

    Long COVID risk seems higher in those with repeated infections or underlying health conditions, but it can affect previously healthy individuals as well.​

    This possibility is one reason experts continue to encourage vaccination, early testing, and supportive care, for example, resting adequately and returning to activity gradually, to help reduce the chances of prolonged recovery.

    Ongoing research is tracking how each new COVID-19 variant may influence long-term outcomes, but the consistent message is that preventing infection and reinfection remains important.​

    Staying Ahead of New COVID-19 Symptoms in 2026

    COVID-19 in 2026 is no longer defined by the dramatic hospital scenes of the earliest waves, yet each new COVID-19 variant continues to bring a familiar set of respiratory symptoms that can still disrupt health, work, and daily life.

    Staying up to date on vaccines, improving indoor ventilation, using well‑fitting masks during surges or in crowded indoor spaces, and testing when symptoms arise are practical ways to reduce personal and community risk.​

    By recognising how new COVID-19 symptoms typically present, especially intense sore throat, persistent congestion, and extended fatigue, people can decide sooner when to test, when to isolate, and when to seek medical advice.

    These steps help limit the impact of COVID-19 in 2026, even as the virus continues to evolve through each new COVID-19 variant.​

    Frequently Asked Questions

    1. Can someone have COVID without a positive test?

    Yes. Rapid antigen tests can miss some infections, especially early or late in the course of illness, or if the swab technique is poor. If symptoms strongly suggest COVID-19 in 2026 and there is known exposure, health authorities often recommend repeating testing over a couple of days or using a lab-based PCR test for higher sensitivity.​

    2. Does getting COVID-19 in 2026 from a new variant change how long a person is contagious?

    Current evidence suggests most people with Omicron-lineage variants are most contagious from about 1–2 days before symptoms start through the first 5–7 days of illness, similar to earlier Omicron waves.

    People with severe illness or weakened immune systems may shed virus for longer, which is why some guidelines recommend extended isolation or masking in high‑risk situations for these groups.​

    3. Can air purifiers really help reduce the spread of new COVID-19 variants at home?

    Portable HEPA air purifiers can meaningfully reduce virus-containing aerosols in indoor air when sized correctly for the room and run on an adequate setting.

    They work best as part of a layered approach, alongside ventilation (open windows or mechanical systems), masking during surges, and prompt isolation when new COVID-19 symptoms appear.​

    4. Is it possible to build long-term immunity against new COVID-19 symptoms and variants?

    Immunity from vaccination and past infection continues to reduce the risk of severe disease, even as new COVID-19 variants emerge and partly evade antibodies. However, protection against infection and mild symptomatic illness tends to wane over months, which is why updated booster doses and periodic exposures still play a role in keeping immune responses refreshed.​



    Source link